about
The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myelomaHigh Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients.Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis.Gamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma cells.EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.Role of micro-RNAs in drug resistance of multiple myeloma.Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction.The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains.1,2,3,4,6-Penta-O-Galloyl-Beta-D-Glucopyranoside Inhibits Proliferation of Multiple Myeloma Cells Accompanied with Suppression of MYC Expression.Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells
P2860
Q33838260-8D5CADD9-3D0C-401B-A1DC-092E44943B93Q34956692-B0653F48-8F05-45E3-B0C4-C6B658A4C584Q35097105-F3F62B36-084E-454A-BDD0-804AB5ABCFECQ35778422-D14047A2-289C-42A5-AAF3-FC0F2CA012F8Q36210986-07B6F3A0-33F2-4C5C-B620-A2CEDF572CDDQ37085867-65337652-F5CC-45FF-AE0C-36FA3BC253AEQ37705811-B3FD958E-E91E-4B58-9A0D-B23AC8C39411Q38854653-A352F992-02F2-4E07-8777-34EAF354958DQ38862552-F67873FA-9595-4C60-8B3E-A4602159B058Q38919670-5454CA6B-0BF9-4C81-83A8-7F0FD1E84155Q38926653-2A7A47B6-22F5-435A-BE1C-F8DAC78BEF91Q47101382-B86B21CB-BBC7-4EA2-8F37-EE2092FA16CAQ50199534-AA35579D-FA8A-4185-857F-383A5D852AF9Q58719353-BC21BAD2-6CB4-4CCF-AA1C-B1A3E3F89CF7
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Oncogene addiction to c-MYC in myeloma cells.
@en
Oncogene addiction to c-MYC in myeloma cells.
@nl
type
label
Oncogene addiction to c-MYC in myeloma cells.
@en
Oncogene addiction to c-MYC in myeloma cells.
@nl
prefLabel
Oncogene addiction to c-MYC in myeloma cells.
@en
Oncogene addiction to c-MYC in myeloma cells.
@nl
P2860
P356
P1433
P1476
Oncogene addiction to c-MYC in myeloma cells.
@en
P2093
Anders Sundan
P2860
P304
P356
10.18632/ONCOTARGET.631
P407
P50
P577
2012-08-01T00:00:00Z